Marketing-authorisation holder · Canada
Gilead Sciences Canada Inc
34 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · Canada
34 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 34
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| BIKTARVY50 mg + 200 mg + 25 mg · Tablet | Bictegravir, Emtricitabine, Tenofovir alafenamide | Canada | Marketed | 2018 |
| CAYSTON75 mg / vial · Powder For Solution | Aztreonam | Canada | Marketed | 2009 |
| COMPLERA200 mg + 25 mg + 300 mg · Tablet | Emtricitabine, Rilpivirine, Tenofovir disoproxil | Canada | Marketed | 2011 |
| DESCOVY200 mg + 10 mg · Tablet | Emtricitabine, Tenofovir alafenamide | Canada | Marketed | 2016 |
| DESCOVY200 mg + 25 mg · Tablet | Emtricitabine, Tenofovir alafenamide | Canada | Marketed | 2016 |
| EPCLUSA400 mg + 100 mg · Tablet | Sofosbuvir, Velpatasvir | Canada | Marketed | 2016 |
| GENVOYA150 mg + 150 mg + 200 mg + 10 mg · Tablet | Cobicistat, Elvitegravir, Emtricitabine, Tenofovir alafenamide | Canada | Marketed | 2016 |
| HARVONI90 mg + 400 mg · Tablet | Ledipasvir, Sofosbuvir | Canada | Marketed | 2014 |
| HEPCLUDEX2 mg / vial · Powder For Solution | Bulevirtide | Canada | Marketed | 2025 |
| LYVDELZI10 mg · Capsule | Seladelpar | Canada | Marketed | 2025 |
| ODEFSEY200 mg + 25 mg + 25 mg · Tablet | Emtricitabine, Rilpivirine, Tenofovir alafenamide | Canada | Marketed | 2017 |
| SOVALDI400 mg · Tablet | Sofosbuvir | Canada | Marketed | 2014 |
| STRIBILD150 mg + 150 mg + 200 mg + 300 mg · Tablet | Cobicistat, Elvitegravir, Emtricitabine, Tenofovir disoproxil | Canada | Marketed | 2012 |
| SUNLENCA309 mg / ml · Solution | Lenacapavir | Canada | Marketed | 2023 |
| SUNLENCA300 mg · Tablet | Lenacapavir | Canada | Marketed | 2023 |
| TECARTUS100000000 cells / bag · Suspension | Brexucabtagene autoleucel | Canada | Marketed | 2023 |
| TECARTUS200000000 cells / bag · Suspension | Brexucabtagene autoleucel | Canada | Marketed | 2021 |
| TRODELVY180 mg / vial · Powder For Solution | Sacituzumab govitecan | Canada | Marketed | 2021 |
| TRUVADA200 mg + 300 mg · Tablet | Emtricitabine, Tenofovir disoproxil | Canada | Marketed | 2006 |
| VEKLURY100 mg / vial · Powder For Solution | Remdesivir | Canada | Marketed | 2020 |
| VEMLIDY25 mg · Tablet | Tenofovir alafenamide | Canada | Marketed | 2017 |
| VIREAD300 mg · Tablet | Tenofovir disoproxil | Canada | Marketed | 2004 |
| VOSEVI400 mg + 100 mg + 100 mg · Tablet | Sofosbuvir, Velpatasvir, Voxilaprevir | Canada | Marketed | 2017 |
| YESCARTA200000000 cells / bag · Suspension | Axicabtagene ciloleucel | Canada | Marketed | 2019 |
| YEYTUO300 mg · Tablet | Lenacapavir | Canada | Authorised |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 34 | 28 | 6 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.